[1] In Mesoblast's annual report from August 2010, the company first announced positive results of preclinical trials showing radiographic and pathologic disc regeneration with MPC-06-ID.
[2] In December 2010, Mesoblast entered into an agreement with U.S.-based Cephalon to develop and commercialize novel adult Mesenchymal Precursor Stem Cell (MPC) therapeutics for degenerative conditions of the cardiovascular and central nervous systems.
[7] [8] In March 2014, Circulation Journal published the results of a clinical trial using MPCs as adjunctive therapy for patients with a Ventricular Assist Device.
The company sold it as an allogeneic cell product for the treatment of acute graft versus host disease (aGVHD) in children and adults in Japan.
[12][13][14][15]In December 2016, Mesoblast and Mallinckrodt Pharmaceuticals entered into an agreement to exclusively negotiate a commercial and development partnership for MPC-06-ID in the treatment of chronic low back pain due to disc degeneration.
[17] A Phase III clinical trial began enrollment on July 22, 2024, of rexlemestrocel-L for patients with chronic low back pain caused by inflammatory degenerative disc disease.